The risky reliance on small surrogate endpoint studies when planning a large prevention trial
{{output}}
The definitive evaluation of treatment to prevent a chronic disease with low incidence in middle age, such as cancer or cardiovascular disease, requires a trial with a large sample size of perhaps 20,000 or more. To help decide whether to implement a large tru... ...
